A5093764855- Cancer therapeutics and mechanisms
- Neuroendocrine Tumor Research Advances
- Lung Cancer Research Studies
- Bacillus and Francisella bacterial research
- Ubiquitin and proteasome pathways
- Telomeres, Telomerase, and Senescence
- Trace Elements in Health
- Protein Degradation and Inhibitors
- Histone Deacetylase Inhibitors Research
University Hospital Cologne
2024
University of Cologne
2024
Abstract ANTXR1 is one of two cell surface receptors mediating the uptake anthrax toxin into cells. Despite substantial research on its role in poisoning and a proposed function as collagen receptor, ANTXR1’s physiological functions remain largely undefined. Pathogenic variants lead to rare GAPO syndrome, named for four primary features: Growth retardation, Alopecia, Pseudoanodontia, Optic atrophy. The disease also associated with complex range other phenotypes impacting cardiovascular,...
Abstract Treatment-naïve small cell lung cancer (SCLC) is typically susceptible to standard-of-care chemotherapy consisting of cisplatin and etoposide recently combined with PD-L1 inhibitors. Yet, in most cases, SCLC patients develop resistance first-line therapy alternative therapies are urgently required overcome this resistance. In study, we tested the efficacy dinaciclib, an FDA-orphan drug inhibitor cyclin-dependent kinase (CDK) 9, among other CDKs, SCLC. Furthermore, report on a newly...
The 12th Tuscany Retreat on Cancer Research and Apoptosis was held August 19–26, 2023. biennial retreat aims to bring together scientists who advance research in cancer, cell death, neurodegenerative diseases. Topics covered ranged from drug resistance cancer insights into novel molecular signaling mechanisms targets, all related the pathways molecules that regulate programmed death diseases result dysregulation of death. In this meeting review, we summarize content most recent retreat.
Abstract Purpose Small cell lung cancer (SCLC) has an extremely poor prognosis. Despite high initial response rates to chemotherapy and modest survival improvements with the addition of immune checkpoint inhibitors (ICI), almost all patients experience relapse fatal outcomes. Recent genomic insights uncovered extensive molecular heterogeneity in uniform loss RB1 TRP53 . Additionally, defective DNA mismatch repair (MMR) recently been described some SCLC cases. Here, we generated a novel mouse...